Johnson & Johnson will acquire biotechnology firm Firefly Bio for $1 billion in cash.
The deal integrates Firefly’s degrader antibody conjugate (DAC) platform into J&J’s oncology pipeline.
Firefly’s Firelink™ technology targets difficult-to-treat solid tumors, including those with KRAS mutations.
The platform delivers protein degraders directly to cancer cells to minimize damage to healthy tissue.
This acquisition leverages J&J’s antibody engineering expertise to advance cancer treatment development.